Mounjaro and contraception — the failed-pill window and what to do

Why this matters more than you might think

If you're taking Mounjaro and you're using oral contraception, you have a higher risk of unintended pregnancy than you may realise. The MHRA-approved Summary of Product Characteristics for tirzepatide specifically warns that the efficacy of oral contraceptives may be reduced after starting Mounjaro and after each dose increase, because the medication slows gastric emptying and changes how the pill is absorbed.

That's not a vague theoretical risk — it's a specific, regulator-flagged concern with practical implications. And it sits inside a context that makes it more important still: many women on Mounjaro are also women whose underlying fertility may be improving (especially women with PCOS — see our PCOS guide), and tirzepatide is not safe in pregnancy. The combination of more fertility, less reliable oral contraception, and a contraindicated medication in pregnancy means contraception planning has to be deliberate.

The two separate issues

There are two distinct contraception issues with Mounjaro that often get blurred together:

1. You need effective contraception throughout treatment. Mounjaro should not be continued into pregnancy. Anyone of reproductive age who could become pregnant needs a reliable contraceptive plan in place before starting, and maintained throughout, treatment.
2. The oral contraceptive pill specifically may be less effective on Mounjaro. This is the new, often-overlooked piece. Even if you've been on the pill for years without issue, the way Mounjaro changes gastric emptying creates a specific window where pill absorption may be compromised.

Both need addressing. The first is a general principle of starting any medicine that's not safe in pregnancy. The second is specific to GLP-1/GIP medication and especially to tirzepatide.

The MHRA warning in plain language

The MHRA-approved Mounjaro Summary of Product Characteristics states that the effectiveness of oral contraceptives may be reduced in the period immediately after the first injection and after each dose increase, because tirzepatide slows the rate at which the stomach empties.

In plain language: when your stomach empties more slowly, an oral contraceptive pill may not get absorbed in the predictable way it usually does. This is most pronounced in the 4 weeks after starting tirzepatide and in the 4 weeks following each dose increase.

The recommended response (consistent with broader UK contraception guidance) is to either:

• Use an additional barrier method (condoms) during these 4-week windows, OR
• Switch to a non-oral contraceptive method that doesn't depend on gastric absorption.

The failed-pill windows

Practically, the dose-escalation ladder for Mounjaro means the 'risk windows' come up multiple times in the first few months:

• Weeks 1–4 after starting 2.5 mg. Risk window.
• Weeks 1–4 after stepping up to 5 mg. Risk window.
• Weeks 1–4 after stepping up to 7.5 mg. Risk window.
• Weeks 1–4 after stepping up to 10 mg. Risk window.
• Weeks 1–4 after stepping up to 12.5 mg. Risk window.
• Weeks 1–4 after stepping up to 15 mg. Risk window.

That's potentially six separate 4-week windows over the first 6–12 months, depending on how rapidly your prescriber escalates. A pragmatic, conservative interpretation is to assume the entire dose-escalation phase carries some risk to oral contraceptive efficacy, and to either consistently use a barrier method during it, or simply switch to a non-oral method for the duration of Mounjaro treatment.

What to actually do — practical options

The cleanest practical options, in rough order of how often they're chosen in our clinic:

• Switch to a long-acting non-oral method. The intrauterine system (Mirena, Kyleena), the implant (Nexplanon), or the contraceptive injection (Depo-Provera) all bypass the absorption issue entirely. The IUS and implant are particularly popular because they're 'fit and forget'. Once in place, you don't have to think about the pill timing or remember a backup method during dose escalations. A copper coil is also an option if you prefer non-hormonal contraception.
• Stay on the pill, add barrier method during risk windows. Continue your usual oral contraceptive, and use condoms consistently for 4 weeks after starting Mounjaro and 4 weeks after each dose increase. This works in theory but in practice is harder to sustain because the windows are recurrent and easy to forget.
• Combination: stay on the pill, use barrier method throughout dose escalation. A pragmatic middle ground. Use barrier method consistently for the first 6 months of Mounjaro treatment (i.e. the dose-escalation phase), then return to pill-only at maintenance dose if your prescriber confirms a stable dose.

If you're unsure which option fits your circumstances, a contraception consultation — either with us, your GP, or a sexual and reproductive health clinic — is the practical next step. The FSRH (Faculty of Sexual & Reproductive Healthcare) publishes detailed guidance that your clinician can apply to your specific situation.

Planning a pregnancy — the stopping window

If you're planning to conceive, Mounjaro must be stopped before pregnancy. The MHRA advice is to stop at least 4 weeks before planned pregnancy; some clinicians prefer 6–8 weeks for a margin of safety.

Practical steps:

• Plan ahead. If pregnancy is on the horizon (6–12 months), discuss the stopping plan with your prescriber early.
• Stop taking Mounjaro 4–8 weeks before you start actively trying to conceive.
• During the washout period, continue effective contraception until you're ready for active conception attempts.
• Expect appetite and weight changes after stopping. Without the medication's effects, appetite returns over weeks. The weight-management work you've done is preserved better when paired with maintained eating and activity patterns.
• Pre-pregnancy weight management is its own clinical conversation — your GP and, where indicated, an obstetrician or fertility specialist can help with a plan.

Accidental pregnancy on Mounjaro

If you become pregnant unexpectedly while taking Mounjaro:

• Stop Mounjaro immediately.
• Contact your GP or a midwifery service to confirm the pregnancy and arrange early antenatal care.
• Discuss with your obstetrician any specific monitoring or additional ultrasound that may be appropriate given the in-utero exposure.
• Do not stop seeking care or hide the exposure — the clinical team needs the full picture to give the best advice.

Tirzepatide is not licensed in pregnancy and animal data raised concerns about fetal development. Human data on early-pregnancy exposure is limited; pregnancies on tirzepatide should be reported through the MHRA Yellow Card scheme and discussed with a teratology service such as UK Teratology Information Service (UKTIS) for individual advice.

Why PCOS makes this more urgent

Women with PCOS are over-represented among Mounjaro users — partly because of insulin resistance, weight, and BMI, and partly because PCOS-related symptoms often improve on tirzepatide. As covered in our PCOS guide, one of the most striking effects in this group is the return of regular ovulatory cycles, sometimes after years of irregular or absent periods.

That's a meaningful improvement — and a meaningful fertility risk if pregnancy isn't wanted. Women with PCOS who haven't worried about pregnancy in years may need to think about contraception for the first time in a while. The combination of restored fertility plus reduced oral contraceptive reliability makes a non-oral method (IUS, implant, injection) particularly appealing for many.

Emergency contraception on Mounjaro

If you've had unprotected sex and you're concerned about pregnancy, emergency contraception is available from any pharmacy without prescription. The options are:

• Levonelle (levonorgestrel 1500 mcg). Effective up to 72 hours after unprotected sex; earlier is better.
• ellaOne (ulipristal acetate 30 mg). Effective up to 120 hours (5 days) after unprotected sex; particularly useful if more than 72 hours have passed.
• Copper intrauterine device (IUD). The most effective form of emergency contraception, fitted within 5 days of unprotected sex or up to 5 days after the earliest expected ovulation. Has the added benefit of becoming ongoing contraception.

The slowed gastric emptying caused by Mounjaro could theoretically affect absorption of oral emergency contraception. There isn't strong evidence either way at present, but a pragmatic approach if emergency contraception is needed on Mounjaro is to consider the copper IUD, or to discuss with a clinician whether to take a higher dose of levonorgestrel (off-label) given the absorption uncertainty.

Whatever you do, act quickly — emergency contraception is time-sensitive. Then take a pregnancy test 3 weeks after the unprotected sex to confirm the outcome.

Does this apply to Wegovy too?

Semaglutide (Wegovy) also slows gastric emptying, although the MHRA labelling for oral contraceptive interaction is less prominently flagged than for tirzepatide. The cautious clinical position is that the same broad principles apply — add a barrier method or switch to a non-oral method during initiation and dose escalation — even if the formal labelling is softer. See our Wegovy explainer for more on semaglutide. The dose-escalation ladder is slightly different, but the underlying mechanism is the same family.

HRT, fertility treatment, IVF — brief notes

A few adjacent scenarios that come up in clinic:

• HRT. Oral HRT could in theory be affected by slowed gastric emptying in the same way as the contraceptive pill, though clinical significance is unclear. Transdermal HRT (patches, gel) bypasses the issue entirely. If you're on oral HRT and starting Mounjaro, raise this with your prescriber.
• Fertility treatment. Mounjaro is not compatible with active fertility treatment or pregnancy. The stopping window applies.
• IVF. Pre-IVF weight management can be useful, but Mounjaro must be stopped well before any embryo transfer (typically a minimum 4-week washout, longer is safer). Coordinate timing carefully with your fertility specialist.

The bigger picture

The contraception conversation is one of several safety topics that mean Mounjaro really does need a structured programme around it — not a pen-only online prescription. Other safety topics include monitoring through dose escalation (see our month-by-month side effects guide), the implications of switching from another GLP-1 medication (see switching from Wegovy), and the choice between MHRA-licensed options (see Mounjaro vs Wegovy).

Together these are the conversations a responsible prescriber should be having with you before you start. If a service is dispensing pens without covering them, the absent safety advice is part of what you're not paying for — and you're carrying the risk personally.

The next step

If you're considering Mounjaro and you need to think through contraception, the most useful single step is a 30-minute consultation. Bring details of your current contraception (method, brand, how long you've been on it), any fertility plans (current or future), and your medical history. We'll walk through the options, agree a plan that fits your circumstances, and — if appropriate — start a structured Mounjaro programme with the right contraceptive scaffolding in place from day one.